A first test of a pill called ONC206 for brain and spinal cord tumors that came back
Original title: Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early safety and dose test in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing a pill called ONC206 in people whose brain or spinal cord tumor came back.
Who this trial is for. This trial is for people with a primary brain or spinal cord tumor that came back. Some of these tumors are rare. It tests a pill called ONC206, used on its own, taken weekly or on more than one day each week.
Where it stands. The trial is checking how safe the pill is and how well people handle it. It is also looking for the highest dose people can take, and for side effects that are too strong. Those answers are not in yet. The trial has not reported results.
What this means, and what it doesn't
What it could mean: Nothing about this pill is proven yet. Someone who fits the picture above could ask their care team about it. The care team can say if it makes sense to look into.
What it doesn't mean: This does not mean the pill works. A trial is a test, not a proven treatment. Being in one is not a promise that it will help. It is not a cure.
Source: ClinicalTrials.gov, October 23, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.